# TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

> **NCT00077142** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 37 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** TAC-101

## Key facts

- **NCT ID:** NCT00077142
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04
- **Primary completion:** 2005-07
- **Final completion:** 2005-08
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-10-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077142, "TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00077142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*